Urotensin-II and the cardiovascular system – the importance of developing modulators

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.13.5.479PMID 15155123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

  2004cited by this paper
• Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay

  2003influential reference
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

  2003cited by this paper
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003influential reference
• A Comparison of Cerebrospinal Fluid and Plasma Urotensin II Concentrations in Normotensive and Hypertensive Patients Undergoing Urological Surgery During Spinal Anesthesia: A Pilot Study

  2003cited by this paper
• Central cardiovascular action of urotensin II in spontaneously hypertensive rats.

  2003cited by this paper
• Central cardiovascular action of urotensin II in conscious rats

  2003cited by this paper
• Structure–Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction

  2003cited by this paper
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003influential reference
• Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice

  2003influential reference
• Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

  2003influential reference
• The neuromedin B receptor antagonist, BIM‐23127, is a potent antagonist at human and rat urotensin‐II receptors

  2003influential reference
• UROTENSIN II MEDIATES ERK1/2 PHOSPHORYLATION AND PROLIFERATION IN GPR14-TRANSFECTED CELL LINES

  2002cited by this paper
• Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats.

  2002cited by this paper
• G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors.

  2002cited by this paper
• No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans.

  2002influential reference
• Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

  2002influential reference
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002influential reference
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002influential reference
• Expression of cholecystokinin in the duodenum of patients with coeliac disease: respective role of atrophy and lymphocytic infiltration.

  2002cited by this paper
• High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• A new ligand for the urotensin II receptor

  2002cited by this paper
• Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

  2002cited by this paper
• Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.

  2002cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Cardiovascular effects of urotensin II in different brain areas.

  2002influential reference
• Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

  2002cited by this paper
• Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist

  2002cited by this paper
• Molecular and pharmacological characterization of genes encoding urotensin‐II peptides and their cognate G‐protein‐coupled receptors from the mouse and monkey

  2002cited by this paper
• Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition.

  2001cited by this paper
• Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin‐II

  2001cited by this paper
• Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells

  2001influential reference
• Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats

  2001cited by this paper
• Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries.

  2001influential reference
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase

  2001influential reference
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001influential reference
• Effects of Urotensin II in Human Arteries and Veins of Varying Caliber

  2001cited by this paper
• Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

  2000cited by this paper
• Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.

  2000influential reference
• Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1

  2000influential reference
• Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

  2000influential reference
• Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries

  2000influential reference
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000influential reference
• Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14).

  1999cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999influential reference
• Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14.

  1999cited by this paper
• Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord.

  1998cited by this paper
• TGF-beta signal transduction.

  1998cited by this paper
• Cardiovascular effects of urotensin II in anesthetized and pithed rats.

  1986cited by this paper

• Association between urotensin II gene polymorphism and pre-eclampsia.

  2010cites this paper
• Optimization of isochromanone based urotensin II receptor agonists.

  2010cites this paper
• Urotensin II alters vascular reactivity in animals subjected to volume overload.

  2010cites this paper
• Urotensin-II receptor modulators as potential drugs.

  2010cites this paper
• Generation of novel, potent urotensin-II receptor antagonists by alkylation-cyclization of isoindolinone C3-carbanions

  2009cites this paper
• Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

  2009cites this paper
• Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits.

  2009cites this paper
• Does cigarette smoking increase plasma urotensin II concentrations?

  2007cites this paper
• Design, parallel synthesis and SAR of novel urotensin II receptor agonists.

  2007cites this paper
• Urotensin-II receptor antagonists.

  2006cites this paper
• Novel potent and efficacious nonpeptidic urotensin II receptor agonists.

  2006cites this paper
• Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study.

  2005cites this paper
• Endogenous Vasoactive Peptides

  2003cites this paper